Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 2, 2010, Pages 171-176

  Zhang, Xiao Shan ^a   Ren, Jiang Hua ^a   Lu, Jing Ping ^a   Fan, Ying ^b  

^a WUHAN UNIVERSITY   (China)

^b Sixth Hospital of Wuhan   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; BRADYKININ B2 RECEPTOR; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ICATIBANT; LACTATE DEHYDROGENASE; NITRIC OXIDE;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEMODYNAMICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOTENSIN II; APOPTOSIS; CELL LINE; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE SYNTHASE TYPE III; PYRROLES; RECEPTOR, BRADYKININ B2; UMBILICAL VEINS;

EID: 77955984656     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e5f2e2     Document Type: Article

References (40)

1. Morishita R, Higaki J, Miyazaki M, et al. Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension. 1992;19(Suppl 2):II62-II67.
2. Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
3. Wolf G, Ziyadeh FN, Zahner G, et al. Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension. 1996;27:897-905.
4. Arnal JF, Michel JB, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens. 1995;4:182-188.
5. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 1994;89(Suppl 1):87-102.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
7. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N YAcadSci. 2001;947:167-179; discussion 179-180.
8. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37(2 pt 2): 767-773.
9. Ichiki T, Usui M, Kato M, et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998;31(1 pt 2): 342-348.
10. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
11. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
12. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
13. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996;271: 5289-5292.
14. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther. 1992;56:131-190.
15. Blaukat A. Structure and signalling pathways of kinin receptors. Andrologia. 2003;35:17-23.
16. Shiga N, Hirano K, Hirano M, et al. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res. 2005;96:1014-1021.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
18. Nolly H, Carbini LA, Scicli G, et al. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994;23(6 pt 2):919-923.
19. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005;99:6-38.
20. Su JB, Houel R, Heloire F, et al. Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. Circulation. 2000;101:1848-1853.
21. Kato M, Shiode N, Yamagata T, et al. Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis. Heart. 1997;78:493-498.
22. Rosenkranz AC, Hood SG, Woods RL, et al. Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension. 2002;40:498-503.
23. Kuoppala A, Shiota N, Lindstedt KA, et al. Expression of bradykinin receptors in the left ventricles of rats with pressure overload hypertrophy and heart failure. JHypertens. 2003;21:1729-1736.
24. Kuoppala A, Shiota N, Kokkonen JO, et al. Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol. 2002;40: 119-125.
25. Grbovic L, Djokic J, Radenkovic M, et al. Analysis of the vasorelaxant action of angiotensin II in the isolated rat renal artery. J Pharmacol Sci. 2008;106:376-384.
26. Katada J, Majima M. AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol. 2002;136:484-491.
27. Hannan RE, Davis EA, Widdop RE. Functional role ofangiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol. 2003; 140:987-995.
28. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35:155-163.
29. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodila-tion. J Clin Invest. 1999;104:925-935.
30. AbdAlla S, Lother H, Abdel-tawab AM, et al. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276:39721-39726.
31. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729.
32. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97: 1129-1135.
33. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
34. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103: 113-118.
35. Marino F, Guasti L, Cosentino M, et al. Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008;26:1147-1155.
36. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA. 2002;99: 8301-8305.
37. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition ofprotein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22:8467-8477.
38. Adler S, Huang H, Trochu JJN, et al. Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure. Am J Physiol Renal Physiol. 2001;281:F802-F809.
39. Trochu JJN, Mital S, Zhang X, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res. 2003;60: 250-258.
40. Liesmaa I, Kokkonen JO, Kovanen PT, et al. Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 2007;43:593-600.